arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Bausch Health Companies Inc.

BHC
$5.65 ▼ -0.07 (-1.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

Bausch Health Companies Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.1B
Dividend Yield —
Revenue Growth 6.7% ↘
Op. Margin 17.7% ↗
ROIC 2.9% ↗
FCF / Share $2.70 ↘
Trailing P/E 13.5x
Price / Book —
FCF Yield 47.9%
Debt / Equity -37.58
info Valuation on last close. End-of-day price, Sep 24, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.27B
↑ +6.7% —
Net Income Profit after all expenses
$157.00M
↑ +441.3% —
Operating Margin Operating profit as % of sales
17.7%
↑ +9.9% 72th
FCF / Share Free cash flow per share
$2.70
↓ -21.0% —
Long-Term Debt Long-term obligations
$20.82B
↓ -3.7% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability →
56
Returns ↑
24
Financial Health ↑
77
Cash Quality
96

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 19 years · 72 quarters